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Abstract: A set of solanidine analogs with antiproliferative properties were recently 
synthetized from pregnadienolone acetate, which occurs in Nature. The aim of the present 
study was an in vitro characterization of their antiproliferative action and an investigation 
of their multidrug resistance-reversal activity on cancer cells. Six of the compounds 
elicited the accumulation of a hypodiploid population of HeLa cells, indicating their 
apoptosis-inducing character, and another one caused cell cycle arrest at the G2/M phase. 
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The most effective agents inhibited the activity of topoisomerase I, as evidenced by 
plasmid supercoil relaxation assays. One of the most potent analogs down-regulated the 
expression of cell-cycle related genes at the mRNA level, including tumor necrosis factor 
alpha and S-phase kinase-associated protein 2, and induced growth arrest and DNA 
damage protein 45 alpha. Some of the investigated compounds inhibited the ABCB1 
transporter and caused rhodamine-123 accumulation in murine lymphoma cells transfected 
by human MDR1 gene, expressing the efflux pump (L5178). One of the most active agents 
in this aspect potentiated the antiproliferative action of doxorubicin without substantial 
intrinsic cytostatic capacity. The current results indicate that the modified solanidine 
skeleton is a suitable substrate for the rational design and synthesis of further innovative 
drug candidates with anticancer activities. 
Keywords: solanidine analog; anticancer action; efflux pump 
 
1. Introduction 
Molecules with a steroidal skeleton exert an exceptionally wide range of pharmacological activities, 
despite their highly conserved chemical structures. Besides the well-characterized hormonal actions 
(e.g., sexual steroids, gluco- and mineralocorticoids), many steroids isolated from plants exert a broad 
variety of pharmacological actions, including antioxidant, neuroprotective, antihypercholesterolemic 
and ionotropic properties [1–5]. Antiproliferative activities are among the most intensively 
investigated properties of natural products and their synthetic analogs; the importance of such studies 
may be illustrated by the fact that nearly 80% of all the recently approved anticancer agents are either 
natural products or their synthetic analogs [6]. Cardiotonic steroids (e.g., digoxin and digitoxin) are 
traditionally utilized in cardiovascular medicine and their pronounced antiproliferative activities were 
recently recognized in retrospective epidemiological analyses. During the last decade, intensive 
research has paved the way for their further development and their application for cancer prevention or 
treatment [7]. A continuously increasing number of chemically diverse natural steroidal products with 
antiproliferative activities have been isolated, but most do not have substantial effects on the classical 
hormonal receptors [8]. The most promising of these natural compounds have been used for the design 
and synthesis of a wide variety of novel analogs with a view to understanding the structure–activity 
relationships in order to optimize the structure. Steroidal alkaloids are characteristic secondary 
metabolites commonly found in species of the Solanaceae, Apocynaceae, Liliaceae and Dioscorea 
families. The antiproliferative capacities of the most abundant molecules, including diosgenin, 
solasodine and tomatidine, against human cancer lines are well characterized [9]. Locally applied 
solasodine glycosides have been investigated in a double-blind, randomized and placebo-controlled 
clinical study on patients with basal cell carcinoma. The cream was found to be effective in the 
histologically confirmed clearance of the cancer cells, and 78% of the patients had had no recurrence at 
the 1-year follow-up [10]. In a separate subset of innovative steroid-based anticancer agents, the 
steroid backbone has been utilized as a carrier and linked to a cytotoxic pharmacophore (e.g., a 
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nitrogen mustard moiety). This type of drug candidate is typically designed for targeting of  
estrogen- and androgen-dependent cancers [11].  
In a project designed to find novel lead-candidates, androstane-based analogs were designed and 
their antiproliferative properties were screened [3,12–15]. A set of solanidine analogs were synthetized 
from pregnadienolone acetate (which occurs in Nature) and subjected to a preliminary study of their 
cytostatic activities against human adherent cancer cell lines [15,16]. The starting material of the 
synthesis was recently produced from an extract of the fermentation broth of an endophytic fungus, 
Sphaceloma sp. LN-15, isolated from the leaves of Melia azedarach L. and cultivated in pure culture [17]. 
The aim of the present study was the characterization of the antiproliferative action of these novel 
solanidine analogs. Their proposed mechanisms of action were approximated by means of a set of  
in vitro experiments including flow-cytometric cell cycle analyses, plasmid supercoil relaxation assays 
and RNA profiling with nanocapillary, quantitative real-time PCR (QRT-PCR).  
Multidrug resistance (MDR), which is usually manifested as a consequence of the overexpression 
of ATP-binding cassette (ABC) efflux transporters, is one of the greatest challenges in the 
development of anticancer drugs. Inhibition of such efflux pumps may be regarded as an approach to 
reverse MDR and therefore restore the efficacy of the utilized anticancer drugs [18]. ABCB1 (also 
known as P-glycoprotein or P-gp), is frequently involved in MDR is the most intensively studied 
transporter of this class. Since chemically related steroidal compounds have been reported to inhibit 
the ABCB1 efflux pump, the rhodamine-123 exclusion assay was used in order to extend our 
investigations to the MDR-reversal properties of the current set of solanidine analogs [19].  
2. Results and Discussion 
2.1. Cell Cycle Analysis 
The chemical structures of the currently investigated set of solanidine analogs are presented in Figure 1.  
Figure 1. Chemical structures of solanidine (left) and the tested analogs (right). 
 
Compound R1 R2 R3 R4 
Antiproliferative 
Potency 1 
1 H H H CH3  
2 H H H CH(CH3)2  
3 H H H OCH3  
4 H H H CN  
5 H H OCH3 H  
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Figure 1. Cont. 
Compound R1 R2 R3 R4 
Antiproliferative 
Potency 1 
6 H H H OCF3  
7 H CH3 H CH3  
8 Ac H H OCF3  
9 Ac CH3 H CH3  
10 2 Ac NO2 H NO2  
11 H H H CF3  
12 H H H Cl  
13 H H H NO2  
14 H H H H – 
15 H CH3 H OCH3  
16 Ac H H H – 
17 Ac CH3 H OCH3 – 
18 2 Ac H H CN – 
1 Calculated IC50 values against HeLa cells are below 10 µM (), between 10 and 30 µM () or above  
30 µM (–). For exact values see [16]; 2 Containing a pyrazolidine ring instead of a 2-pyrazoline.  
On the basis of previous evaluations of their antiproliferative potencies, 10 of them were selected 
for flow-cytometric cell cycle analyses at two concentrations (10 and 30 µM). Treatment of HeLa cells 
with compounds that had previously exhibited IC50 values < 10 µM generally elicited a profound 
change in the cell cycle distribution (Figure 2). The most outstanding action detected was the 
substantial increase in the hypodiploid (subG1) population. In this respect, compound 6 was the most 
potent one, causing a significant elevation of the hypodiploid population even at the lower 
concentration. Comparison of the results obtained with pairs of molecules differing only in the 
substituents at position 3 (i.e., pairs 6 and 8; 7 and 9) revealed that a hydroxy group is more favorable 
than an acetoxy function. The other cell cycle phases were not substantially disturbed by the treatment 
with the tested compounds, with the exception of 10, which elicited a cell cycle arrest as indicated by a 
concentration-dependent decrease in the G1 population and an increase in the G2/M cells. 
2.2. Plasmid Supercoil Relaxation Assay 
Supercoil relaxation assay screening of some of the selected test compounds involved monitoring as 
discrete bands for supercoiled (sc) and relaxed (rlx) DNA separated in gel electrophoresis. Inhibition 
of the relaxation activity was detected in the form of sc DNA, migrating faster than rlx DNA (Form I). 
A representative gel analysis of the supercoil relaxation activity of DNA topoisomerase I in the 
presence of 0.1 mM of the compounds is given in Figure 3. The relaxation of the sc plasmid substrate, 
pBR322, by topoisomerase I (Figure 3, lane 2) was not influenced by the presence of DMSO (Figure 3, 
lane 3), which was used for the dissolution of the test compounds. However, relaxation of sc pBR322, 
was profoundly affected upon incubation with 3, 4 and 14, as evidenced by the average 65%, 61% and 
56% of sc pBR322 remaining, respectively, in the form of Form I DNA, obtained from the relative 
band intensities of Form I and Form II DNA (Figure 3). Among the other test compounds, 2 and 12 
exerted intermediate interference, while 1 had only a negligible effect on the relaxing ability of the 
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enzyme (Figure 3). Residual Form II DNA, seen in the sc pBR322 preparation, was taken into 
consideration by subtracting from the band intensity corresponding to the relaxation of the enzyme for 
each test compound. The lower concentrations of the test compounds gave rise to a decreased band 
intensity of Form I DNA, with an accumulation as slower-migrating Form II DNA, demonstrating the 
concentration-dependent nature of the effects (data not shown). 
Figure 2. Effects of 1–10 on the HeLa cell cycle distribution after 24 h at 10 (open 
columns) and 30 µM (filled columns). Panels A, B, C and D indicate cells in subG1, G1, S 
and G2/M phase, respectively. * and ** indicate p < 0.05 and p < 0.001, respectively, as 
compared with the control cells.  
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Figure 3. The effects of the solanidine analogs on mammalian DNA topoisomerase I 
activity. A representative agarose gel photograph of supercoil relaxation in the presence of 
0.1 mM concentrations of the test substances. Lane 1, pBR322; lane 2, pBR322 with 1 u of 
DNA topoisomerase I; lane 3, same as lane 2 with DMSO, lanes 4 to 9, pBR322 with 1 u 
DNA topoisomerase I in the presence of 0.1 mM of 14, 12, 3, 1, 4 and 2, respectively. 
 
2.3. RNA Profiling with High-Throughput Nanocapillary QRT-PCR 
To study the effects of the different steroid compounds, it seemed appropriate to focus on a subset 
of genes that may serve screening purposes for specific cell cycle markers. The aim of the present 
study was to analyze the effects of different steroids at different concentrations and time points with 
multiple repetitions, and we therefore applied a customized nanocapillary QRT-PCR platform to 
profile cell cycle- and apoptosis-related genes in response to drug intervention. Accordingly, from the 
DNA-microarray and literature data we selected 56 genes that cover different pathways which undergo 
changes during the cell cycle and which have roles in apoptosis; cyclin-dependent protein kinases 
(CDC2, CDK2, CCNH, CCND1, cyclin E2, CKS1B and CKS2), DNA and chromatin binders 
(MCM3,5, PCNA, BRCA1 and BRCA2), DNA repair (HUS1, GADD45a and RAD17), TNF and 
death receptors (TNFRSF1B, TNFRSF4, TNF, TNFRSF10A and TNFRSF10B), transcription factors 
(EGR1, TP73, FOXOA3, CDKN2A, CDKN2B, CCNT1 and CCNT2), kinases (EGFR, ABL1, 
DAPK2 and DAPK3) and ubiquitin-dependent proteins (UBE1, APC2, APC4 and SKP2). The list of 
the selected genes, together with their functional categories and primer sequences, can be seen in 
Supplementary Table 1. 
Two analogs (10 and 16, which are one of the most effective and ineffective, respectively) were 
applied at three different concentrations (10 μM, 20 μM and 30 μM) and their effects on the cell  
cycle-related gene expression were determined at three time points (6 h, 12 h and 24 h following 
treatment). Only eight of the selected 56 genes were observed to exhibit changes in expression  
(Table 1). At 6 h, only one gene displayed a changed expression: cyclin-dependent kinase inhibitor 2B 
(CDKN2B) was induced 2.27-fold in the case of 16 at the highest dose, but this change proved to be 
only just at the significance level. At 12 h, only two genes exhibited differential expression, with 
compound 10 down-regulating the expression of tumor necrosis factor alpha (TNFα) in a 
concentration-dependent manner, which suggested not only cytostatic, but also anti-inflammatory 
action, while both 10 and 16 slightly induced the expression of S-phase kinase-associated protein 2 
(SKP2) at 30 μM. Interestingly, at 24 h the expression of the same gene was dramatically decreased in 
response to treatment with 10. One of the key players regulating cell cycle progression is the F-box 
protein SKP2. Its protein level is regulated during the cell cycle. Moreover, the overexpression of 
SKP2 is associated with a variety of human cancers, indicating that SKP2 may contribute to their 
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development [20,21]. The down-regulation of SKP2 has been correlated with the induction of 
apoptosis in lung-cancer cells [22]. 
Table 1. QRT-PCR analysis of cell cycle related genes in response to drug treatment. 
  10 
  6-h incubation 12-h incubation 24-h incubation 
GeneName RefSeqID 10 M 20 M 30 M 10 M 20 M 30 M 10 M 20 M 30 M 
TNFα; tumor necrosis factor alpha NM_000594 −1.02 −1.08 −1.23 1.51 −3.90 −8.41 1.72 −1.87 −4.00 
GADD45alpha NM_001924 1.59 1.04 1.24 1.16 1.28 1.72 1.14 5.19 3.65 
TXNRD1; thioredoxin reductase 1 NM_003330 1.24 −1.73 −1.11 −1.40 −1.39 −1.42 1.78 1.90 1.28 
SKP2; S-phase kinase-assoc. prot. 2 NM_005983 1.87 −1.55 −1.43 −1.06 −1.53 2.11 −4.58 −7.60 −8.04 
APC4; anaphase-promoting complex 4 NM_013367 1.31 1.25 1.22 1.27 1.45 1.03 −2.45 −2.16 −2.23 
CCND1; cyclin D1 NM_053056 −1.42 1.05 −1.04 1.25 1.57 −1.30 −1.43 −2.14 −4.36 
CCNE2; cyclin E2 NM_057749 1.04 −1.12 1.09 1.24 1.23 −1.08 1.23 1.13 −1.23 
CDKN2B; cyclin-dependent kinase inhib. 2B NM_078487 −1.22 −1.26 1.27 1.05 −1.50 1.02 −2.74 −7.11 −9.36 
  16 
  6-h incubation 12-h incubation 24-h incubation 
GeneName RefSeqID 10 M 20 M 30 M 10 M 20 M 30 M 10 M 20 M 30 M 
TNFα; tumor necrosis factor alpha NM_000594 1.56 -1.76 −1.69 −1.13 −1.72 −1.75 −2.23 1.16 1.45 
GADD45alpha NM_001924 −1.02 1.12 1.27 1.67 1.38 −1.07 1.78 1.86 2.63 
TXNRD1; thioredoxin reductase 1 NM_003330 1.01 1.14 1.01 1.68 −1.18 1.37 2.42 2.01 2.60 
SKP2; S-phase kinase-assoc. prot. 2 NM_005983 1.03 −1.08 1.67 1.74 1.34 2.10 −1.40 −1.87 −1.30 
APC4; anaphase-promoting complex 4 NM_013367 −1.10 1.26 1.43 1.75 1.08 1.11 −1.28 −1.90 −1.43 
CCND1; cyclin D1 NM_053056 1.15 1.11 1.63 1.07 1.22 1.09 −1.60 −1.01 −1.19 
CCNE2; cyclin E2 NM_057749 1.09 1.30 1.48 1.94 1.44 1.83 −1.33 −2.62 −2.33 
CDKN2B; cyclin-dependent kinase inhib. 2B NM_078487 1.69 1.18 2.27 -1.61 1.96 1.88 −6.22 −7.86 −14.83 
After a 24-h incubation, the up-regulation of the expression of thioredoxin reductase 1 (TXNRD1) 
by 16 indicated the induction of oxidative stress and the related defense mechanism by the cell [23]. 
Both of the steroids were observed to induce growth arrest and DNA damage protein 45 alpha 
(GADD45 alpha). The GADD45 family of proteins, which includes α-, -, and γ-isoforms, has 
recently been shown to play roles in apoptosis, the DNA damage response and cell cycle arrest. 
Moreover, the expression of either GADD45alpha or GADD45gamma activated the P38 and JNK 
kinase pathways and induced G2/M arrest [24]. 
2.4. Rhodamine-123 Accumulation Assay 
The effects of the solanidine analogs on the intracellular accumulation of rhodamine-123 were 
investigated at two concentrations (40 and 400 μM) on a mouse lymphoma cell line (L5178) 
expressing the functional ABCB1 transporter (Table 2). From the perspective of the transporter-
inhibiting property, the functionality at position 3 appears crucial, as reflected by the lower activities of 
the acetylated analogs (compounds 8, 9, 16, 17) relative to those of the hydroxy congeners 
(compounds 6, 7, 14, 15). Of these analogs, 4, 5, 13 and 15 proved to have the most efficient MDR-
reversal effects, resulting in a more than 100-fold increase in rhodamine-123 accumulation with at 
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least one of the applied concentrations. On the other hand, compounds 2, 8 and 17 exerted no effect on 
the pump function. Some of the compounds (e.g., 14 and 15) influenced the accumulation of the 
marker with an apparently inversely proportional concentration–effect relationship. The exact 
mechanism of this behavior is beyond the scope of the present study, but toxicity at the higher 
concentration seems a plausible explanation.  
Table 2. Effects of solanidine analogs on the rhodamine-123 accumulation assay in L5178 MDR 
mouse lymphoma cells. Each datum is the mean ± SEM of the results of three experiments. 
Compound 
Concentration 
(µM) 
Fluorescence 
activity ratio 
 Compound
Concentration 
(µM) 
Fluorescence 
activity ratio 
1 
40 
400 
3.71 ± 0.96 
50.15 ± 7.62 
 11 
40 
400 
4.72 ± 0.53 
84.03 ± 14.22 
2 
40 
400 
1.38 ± 0.11 
6.86 ± 0.96 
 12 
40 
400 
28.74 ± 8.31 
49.07 ± 19.09 
3 
40 
400 
40.68 ± 13.82 
2.27 ± 0.37 
 13 
40 
400 
2.52 ± 0.06 
187.6 ± 51.67 
4 
40 
400 
169.6 ± 43.77 
106.1 ± 17.11 
 14 
40 
400 
36.31 ± 9.56 
14.33 ± 1.20 
5 
40 
400 
51.60 ± 12.57 
114.4 ± 26.51 
 15 
40 
400 
135.1 ± 48.35 
4.58 ± 0.58 
6 
40 
400 
2.91 ± 1.76 
10.16 ± 2.77 
 16 
40 
400 
12.25 ± 3.66 
50.24 ± 3.75 
7 
40 
400 
30.59 ± 10.05 
44.90 ± 16.08 
 17 
40 
400 
1.72 ± 0.46 
7.27 ± 2.30 
8 
40 
400 
1.62 ± 0.15 
2.82 ± 0.94 
 18 
40 
400 
6.74 ± 1.70 
21.98 ± 4.33 
9 
40 
400 
3.16 ± 1.34 
17.15 ± 3.67 
 Verapamil 40.6 5.93 ± 1.92 
2.5. Combination Experiments 
In order to obtain further information concerning the potential importance of the ABCB1-inhibiting 
capacity of the compounds, combination experiments were performed with doxorubicin, a substrate of 
the pump. The antiproliferative potency of doxorubicin against both transfected and parental mouse 
lymphoma cells was determined by means of the MTT assay, which indicated IC50 values of 0.75 and 
0.15 μM, respectively, revealing that the ABCB1 transporter confers resistance against the substrate 
(Figure 4, panel A). A minimally effective concentration of doxorubicin was selected for combination 
with the currently tested solanidine analogs in a 72-h MTT assay. The overall action of 0.1 μM 
doxorubicin (which alone elicits ~7% inhibition of the proliferation of transfected cells) in 
combination with 5 μM of the analogs is presented in Figure 4, panel C. Three of the tested steroids 
that most efficiently inhibited the ABCB1 pump substantially increased the antiproliferative action of 
doxorubicin. In theory, this potentiating action may be attributed to the MDR-reversal properties of the 
steroids or their direct cytostatic action. To answer this, direct antiproliferative actions of these three 
substances were evaluated under the same conditions (Figure 4, panel B). Two of the selected 
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compounds, 3 and 4, proved to exert intrinsic antiproliferative activities with calculated IC50 values of 
1.71 and 5.73 µM, respectively, while 5 did not exhibit any substantial action on the growth of the 
treated cells. 
Figure 4. (A) Antiproliferative action of doxorubicin against parental (□) and MDR (■) 
mouse lymphoma cells; (B) Antiproliferative actions of 3 (□), 4 (■) and 5 () against 
MDR mouse lymphoma cells; and (C) Antiproliferative effects of the solanidine analogs 
(1–9 and 11–18, 5 µM) combined with 0.1 µM doxorubicin.  
 
2.6. Discussion 
There is increasing evidence of the anticancer potential of both natural and synthetic steroidal 
molecules. We have presented here in vitro results concerning the antiproliferative action of 18 
recently synthetized solanidine analogs. Some of them proved able to increase the hypodiploid 
population after a 24-h incubation, which is generally regarded as a marker of programmed cell death, 
corresponding to the apoptosis-inducing capacity of these steroids. The mechanism of the 
antiproliferative action was approached through a set of additional in vitro experiments.  
During recent years, a number of naturally occurring and synthetic compounds with cytotoxic 
properties have been reported to interfere with normal DNA topoisomerase functions [25,26]. These 
enzymes regulate conformational changes in DNA topology by making transient breakages at nucleic 
acid backbone and rejoining of DNA strands. The identification of new compounds with the ability to 
interfere with the catalytic cycle of topoisomerases and to stabilize the covalent complex has therefore 
been recognized as an effective approach for the development of chemotherapeutic agents. We 
biochemically addressed the potential interference of the compounds on DNA topoisomerase reactions 
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via plasmid DNA relaxation assay. Since the plasmid supercoil relaxation assay results agreed well 
with those of cell cycle analyses, topoisomerase I can be regarded as potential target of the tested 
compounds. Indeed, given the crucial roles of DNA topoisomerases in replication, transcription and 
recombination a considerable number of pharmaceutically important compounds were reported to 
target these enzymes [25,26]. Further experiments were performed by means of high-throughput, 
nanocapillary QRT-PCR. Low sample volumes (33 nL in each well), large numbers of reaction 
chambers, 48 individually addressable submatrices and software-controlled data processing and 
analysis make this system ideal for our screening purposes. This QRT-PCR has a capacity of around 
18000 reactions per day and is optimal for analyzing numerous samples over 56-112 gene markers. We 
earlier demonstrated the utility of a high-throughput, nanocapillary QRT-PCR system (OpenArray™ 
Cycler from Applied Biosystems, previously BioTrove) for drug-induced gene expression 
fingerprinting and in vivo toxicogenomics purposes [27,28]. The results of the present assays indicated 
that the steroids analyzed in the present study exhibited their effects on cell cycle-related genes only 24 h 
after treatment, an observation in good concordance with our observations on their cytotoxic effects. 
Two analogs (10 and 16) behaved differently, i.e., showed changed gene expression profiles but both 
compounds repressed the expression of CDKN2B dramatically after one day of incubation, which 
could at least partially explain their roles in inhibiting cell cycle progression in cancer cells [29]. The 
differential repression of two cyclins (cyclin E2 and cyclin D1, respectively) warrants further study. 
Both genes coding for cyclins possess cyclin-dependent protein kinase regulator activity. Cell cycle 
progression is a highly ordered and tightly-regulated process that involves multiple checkpoints for the 
assessment of extracellular growth signals, cell size and DNA integrity. Both cyclin E2 and cyclin D1 
are positive regulators or accelerators that induce cell cycle progression; whereas inhibition of their 
abnormal expression could result in anticancer effects [30,31]. Only the active compound 10 
dramatically decreased the expression of one of the key players regulating cell cycle progression, the 
F-box protein SKP2 after a 24-h treatment, which could partly explain its cytotoxic effect. 
Besides the investigation of the direct antiproliferative action of the current set of solanidine analog, 
their MDR-reversal activities were additionally tested. Since more than half of the analogs caused an 
accumulation of rhodamine-123 comparable to or more pronounced than that of the reference agent 
verapamil, the solanidine-related skeleton can be regarded as a suitable basis for further ABC 
transporter inhibitors. Three of the analogs (compounds 3, 4 and 5) substantially potentiated the 
cytostatic action of doxorubicin against lymphoma cells expressing the human ABCB1 transporter. Since 
compounds 3 and 4 exhibited substantial intrinsic activities their action obtained in combination 
experiments should not be explained by their effects on the ABC transporter. Compound 5 is free of 
intrinsic antiproliferative activity; the advantageous interaction may therefore be attributed to its MDR-
reversal potency. The presented results revealed that substituted androstene-fused arylpyrazolines 
exhibit an attractive array of actions, including antiproliferative, apoptosis-inducing and ABC 
transporter inhibiting-capacities, making this skeleton attractive for the design and synthesis of further 
innovative drug candidates. 
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3. Experimental  
3.1. Cancer Cell Lines 
Human adenocarcinoma cells (HeLa, purchased from the European Collection of Cell Cultures, 
Salisbury, UK) were maintained in minimal essential medium supplemented with 10% fetal bovine 
serum, 1% non-essential amino acids and an antibiotic-antimycotic mixture. A mouse lymphoma cell 
line (L5178) transfected with the human MDR1 gene was used for the measurement of MDR reversal. 
The T-cell line lymphoma cells were transfected with the pHa MDR1/A retrovirus as described by 
Pastan et al. [32,33]. The sensitive (denoted PAR for parental) and the resistant (denoted MDR) cells 
were maintained in McCoy’s 5A medium supplemented with 10% heat-inactivated horse serum, 1%  
L-glutamine and an antibiotic-antimycotic combination. All media and supplements were obtained from 
Life Technologies (Paisley, Scotland, UK). The medium of the MDR cells contained colchicine  
(60 ng/mL) to ensure P-gp activity. All cell types were cultured at 37 °C in a humidified CO2 incubator. 
Chemicals, if otherwise not specified, were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). 
3.2. Cell Cycle Analysis 
Flow the determination of cellular DNA content, flow cytometric analysis was used [34]. HeLa 
cells were treated (180,000/condition) and trypsinized after a 24-h exposure, washed with PBS and 
permeabilized by detergent treatment (0.1% Triton X-100 in PBS) for 30 min. DNA was then stained 
with propidium iodide (10 µg/mL) in the presence of RNase (50 µg/mL). The samples were analyzed 
by FACStar (Becton-Dickinson, Mountain View, CA, USA). In each analysis, 20000 events were 
recorded, and the percentages of the cells in the different cell cycle phases (subG1, G1, S and G2/M) 
were calculated by means of winMDI 2.9. Three independent experiments were performed and average 
values were calculated. The subG1 fractions were regarded as the apoptotic cell population [35]. 
3.3. Plasmid Supercoil Relaxation Assays 
Plasmid supercoil relaxation assays were carried out as described previously [36]. Briefly, 20 µL of 
reaction mixture contained one unit of calf thymus topoisomerase I (the activity removing the 
supercoils from 500 ng of sc plasmid substrate in 30 mins at 37 °C), 500 ng of supercoiled (sc) 
pBR322 (Takara, Otsu-Shiga, Japan),in the presence or absence of the 0.1 volume of test compounds 
in reaction buffer (35 mM Tris-HCl (pH 8.0), 72 mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM 
spermidine, and 0.1% bovine serum albumin). The relaxation products were separated on 1% agarose 
gels in TBE buffer (45 mM Tris borate and 1 mM EDTA, pH 8.0) in a horizontal electrophoresis 
apparatus (5 V/cm) (Thermo EC250) and photographed under UV light after staining in ethidium 
bromide (EtdBr) solution (0.5 μg/mL). The relationship between the binding of EtdBr and the amount 
of fluorescence given by sc and relaxed DNA (rlx DNA) under UV light was carried out as described 
earlier [37]. DNA bands were quantified from gel photo images using BioRad Multianalyst (ver. 1.1); 
average band intensities were calculated from 3 independent reactions. 
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3.4. RNA Isolation, cDNA Conversion 
RNA isolation from cells and cDNA synthesis were performed as published previously [27]. 
Briefly, cells (4 × 106) were washed with PBS, then lyzed in RA1 buffer (Machery-Nagel, Bethlehem, 
PA, USA). Total RNA was purified from drug-treated and control cells with AccuPrep™ RNA 
purification kit (Bioneer, Daeleon, Korea) according to the manufacturer’s protocol, except that DNase 
I treatment was incorporated. RNA was eluted with 50 µL RNase-free water at 55 °C. The quality and 
quantity were assessed spectrophotometrically (Nanodrop, Wilmington, DE, USA) and considered 
accepable if the absorption ratio for 260 nm/280 nm was >1.8. After addition of RNase inhibitor, 
samples were stored at −80 °C. For QRT-PCR, total RNA (750 ng) was converted into cDNA with the 
High-Capacity cDNA RT Kit (Applied Biosystems, Foster City, CA, USA) and without purification 
the mixture was diluted with RNase-free water and subjected to nanocapillary QRT-PCR analysis. 
3.5. Profiling of RNAs with High-Throughput, nanOcapillary QRT-PCR 
Amplification of the samples was followed in real time with an OpenArray NT Cycler (BioTrove 
Inc., Woburn, MA, USA/Applied Biosystems) as previously described [28,38]. For our gene set related 
to the cell cycle and apoptosis, individual SybrGreen assays were specified (for genes, functional 
classes and primer sequences, see Supplementary Table 1). Primer probes were synthetized at 
BioTrove for loading in their OpenArray plates in a customer-specified layout. The reverse transcribed 
samples (or water for no template controls) were added to a 384-well plate containing GenAmp Fast 
PCR Master Mix (Applied BioSystems) and OpenArray DLP 5x Remix Solution (BioTrove Inc.) for 
OpenArray amplification. The OpenArray autoloader transfered the cDNA/master mix from the plate 
to the array through-holes by capillary action. Each subarray was loaded with 5.0 μL of Master Mix 
containing 1.2 μL of reverse transcribed cDNA. The array was manually transferred to the OpenArray 
slide case and sealed. The plates were cycled in the OpenArray NT cycler under the following 
conditions: 50 °C for 15 s, 91 °C for 10 min, followed by 50 cycles of 54 °C for 170 s and 92 °C for 45 s. 
The Biotrove OpenArray NT Cycler System software (version 1.0.2) was used with a proprietary 
calling algorithm that estimates the quality of each individual threshold cycle (CT) value by 
calculating a CT confidence value for the amplification reaction. In our assay, CT values with CT 
confidence values < 300 (average CT confidence of the non-target amplification reactions plus 3 
standard deviations) were considered background signals. CT confidence levels higher than 300 were 
considered positive and were analyzed further. Normalization was done by using the average CT 
values of four house-keeping genes (tubulin beta 2A, beta-actin, HPRT, and serpin peptidase inhibitor 
clade B) and gene expression changes were calculated from the averages of four replicate experiments. 
Average values were accepted when the STD was <0.5 times the average. 
3.6. Rhodamine-123 Exclusion Assay 
The MDR-reversal effect was investigated by rhodamine-123 exclusion assay with a flow cytometer 
on L5178 mouse lymphoma cells transfected with the human MDR1 gene and its parent (PAR), drug 
sensitive cells [33,39]. A total of 106/mL cells were incubated with the tested compounds (final 
concentration: 40 or 400 µM) for 10 min and 10 µL of the substrate rhodamine-123 (1 mg/mL) was 
Molecules 2014, 19 2073 
 
 
added to the samples. Cells were incubated for 20 min at 37 °C, washed twice and resuspended in  
0.5 mL of PBS for flow cytometric analysis with a FACStar (Becton-Dickinson). Verapamil (final 
concentration 40.6 µM) was used as a reference compound. The results of 3 independent tests were 
calculated for the treated MDR and PAR cell lines as compared with the untreated cells. The fluorescence 
activity ratio was calculated as the ratio of the fluorescence of the treated and untreated cells. 
3.7. Antiproliferative Assay 
The antiproliferative effects of the solanidine analogs were determined in MTT ([3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]) assays [40]. Briefly, mouse lymphoma cells 
were seeded into 96-well plates at a density of 10,000/well and exposed to the tested agents for 72 h. 
After the incubation period, 20 μL of MTT solution was added and the precipitated formazan crystals 
were solubilized by the addition of 100 µL of 10% sodium dodecylsulfate. Finally, the absorbance was 
read at 545 nm with an ELISA reader. Two independent experiments were carried out with at least five 
parallel experiments, and doxorubicin Ebewe Pharma GmbH (Unterach, Austria) was used as a 
reference drug. 
4. Conclusions  
A set of solanidine analogs 1–18 was recently synthetized from pregnadienolone acetate. These 
compounds proved to increase the hypodiploid population of HeLa cells, indicating their apoptosis-
inducing character. One of the most potent analogs (compound 10) down-regulated the expression of 
cell cycle-related genes at the mRNA level including TNFα and SKP2 and induced GADD45alpha. 
The inhibition of topoisomerase I could be a substantial element of the detected antiproliferative 
action. Moreover, the MDR-reversal capacities of the novel compounds were evidenced by the 
accumulation of rhodamine-123 in an ABCB1 transporter-expressing lymphoma cell line.  
Supplementary Materials 
The list of the selected genes, together with their functional categories and primer sequences can be 
accessed at: http://www.mdpi.com/1420-3049/19/2/2061/s1. 
Acknowledgments 
Financial support from the Hungarian Scientific Research Fund (OTKA K-109293) is gratefully 
acknowledged. This study was financially supported by the European Union and co-financed by the 
European Social Fund; project number: TÁMOP-4.2.2.A-11/1/KONV-2012-0035.  
Author Contributions 
István Zupkó and László G. Puskás conceived and designed the study; Joseph Molnár and Zeki 
Topcu designed the experiments and interpreted the results of experiments; Éva Frank and János Wölfling 
discussed the results, Judit Molnár, Borbála Réthy, Renáta Minorics, Imre Ocsovszki and Tamás Bitó 
performed the experiments; István Zupkó, Zeki Topcu and László G. Puskás wrote the manuscript. 
  
Molecules 2014, 19 2074 
 
 
Conflicts of Interest 
The authors declare no conflict of interest.  
References  
1. Burg, V.K.; Grimm, H.S.; Rothhaar, T.L.; Grosgen, S.; Hundsdorfer, B.; Haupenthal, V.J.; 
Zimmer, V.C.; Mett, J.; Weingartner, O.; Laufs, U.; et al. Plant sterols the better cholesterol in 
Alzheimer’s disease? A mechanistical study. J. Neurosci. 2013, 33, 16072–16087. 
2. Aperia, A. New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target.  
J. Intern. Med. 2007, 261, 44–52. 
3. Minorics, R.; Szekeres, T.; Krupitza, G.; Saiko, P.; Giessrigl, B.; Wölfling, J.; Frank, E.; Zupkó, I. 
Antiproliferative effects of some novel synthetic solanidine analogs on HL-60 human leukemia 
cells in vitro. Steroids 2011, 76, 156–162. 
4. Prokai-Tatrai, K.; Perjesi, P.; Rivera-Portalatin, N.M.; Simpkins, J.W.; Prokai, L. Mechanistic 
investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids 2008, 
73, 280–288. 
5. Rocha, M.; Banuls, C.; Bellod, L.; Jover, A.; Victor, V.M.; Hernandez-Mijares, A. A review on the 
role of phytosterols: New insights into cardiovascular risk. Curr. Pharm. Des. 2011, 17, 4061–4075. 
6. Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new  
anti-cancer agents. Chem. Rev. 2009, 109, 3012–3043. 
7. Mijatovic, T.; van Quaquebeke, E.; Delest, B.; Debeir, O.; Darro, F.; Kiss, R. Cardiotonic steroids 
on the road to anti-cancer therapy. Biochim. Biophys. Acta 2007, 1776, 32–57. 
8. Gupta, A.; Kumar, B.S.; Negi, A.S. Current status on development of steroids as anticancer 
agents. J. Steroid Biochem. Mol. Biol. 2013, 137, 242–270. 
9. Koduru, S.; Grierson, D.S.; van de Venter, M.; Afolayan, A.J. Anticancer activity of steroid 
alkaloids isolated from Solanum aculeastrum. Pharm. Biol. 2007, 45, 613–618. 
10. Punjabi, S.; Cook, L.J.; Kersey, P.; Marks, R.; Cerio, R. Solasodine glycoalkaloids: A novel 
topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel 
group, multicenter study. Int. J. Dermatol. 2008, 47, 78–82. 
11. Saha, P.; Debnath, C.; Berube, G. Steroid-linked nitrogen mustards as potential anticancer 
therapeutics: A review. J. Steroid Biochem. Mol. Biol. 2013, 137, 271–300. 
12. Kádár, Z.; Molnár, J.; Schneider, G.; Zupkó, I.; Frank, É. A facile ‘click’ approach to novel  
15β-triazolyl-5α-androstane derivatives, and an evaluation of their antiproliferative activities  
in vitro. Bioorg. Med. Chem. 2012, 20, 1396–1402. 
13. Kádár, Z.; Kovács, D.; Frank, É.; Schneider, G.; Huber, J.; Zupkó, I.; Bartók, T.; Wölfling, J. 
Synthesis and in vitro antiproliferative activity of novel androst-5-ene triazolyl and tetrazolyl 
derivatives. Molecules 2011, 16, 4786–4806. 
14. Kádár, Z.; Baji, A.; Zupkó, I.; Bartók, T.; Wölfling, J.; Frank, É. Efficient approach to novel  
1α-triazolyl-5α-androstane derivatives as potent antiproliferative agents. Org. Biomol. Chem. 
2011, 9, 8051–8057. 
Molecules 2014, 19 2075 
 
 
15. Frank, É.; Mucsi, Z.; Szécsi, M.; Zupkó, I.; Wölfling, J.; Schneider, G. Intramolecular approach to 
some new D-ring-fused steroidal isoxazolidines by 1,3-dipolar cycloaddition: Synthesis, 
theoretical and in vitro pharmacological studies. New J. Chem. 2010, 34, 2671–2681. 
16. Frank, É.; Mucsi, Z.; Zupkó, I.; Réthy, B.; Falkay, G.; Schneider, G.; Wölfling, J. Efficient 
approach to androstene-fused arylpyrazolines as potent antiproliferative agents. Experimental and 
theoretical studies of substituent effects on BF3-catalyzed intramolecular [3 + 2] cycloadditions of 
olefinic phenylhydrazones. J. Am. Chem. Soc. 2009, 131, 3894–3904. 
17. Zhang, A.L.; He, L.Y.; Gao, J.M.; Xu, X.; Li, S.Q.; Bai, M.S.; Qin, J.C. Metabolites from an 
endophytic fungus sphaceloma sp. LN-15 isolated from the leaves of Melia azedarach. Lipids 
2009, 44, 745–751. 
18. Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of 
chemosensitizers for their reversal. Cancer Cell Int. 2005, 5, 30. 
19. Lavie, Y.; Harel-Orbital, T.; Gaffield, W.; Liscovitch, M. Inhibitory effect of steroidal alkaloids 
on drug transport and multidrug resistance in human cancer cells. Anticancer Res. 2001, 21, 
1189–1194. 
20. Chan, C.H.; Lee, S.W.; Wang, J.; Lin, H.K. Regulation of Skp2 expression and activity and its 
role in cancer progression. ScientificWorldJournal 2010, 10, 1001–1015. 
21. Wang, Z.; Fukushima, H.; Inuzuka, H.; Wan, L.; Liu, P.; Gao, D.; Sarkar, F.H.; Wei, W. Skp2 is a 
promising therapeutic target in breast cancer. Front. Oncol. 2012, 1, 57. 
22. Yokoi, S.; Yasui, K.; Iizasa, T.; Takahashi, T.; Fujisawa, T.; Inazawa, J. Down-regulation of 
SKP2 induces apoptosis in lung-cancer cells. Cancer Sci. 2003, 94, 344–349. 
23. Pennington, J.D.; Jacobs, K.M.; Sun, L.; Bar-Sela, G.; Mishra, M.; Gius, D. Thioredoxin and 
thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr. Pharm. Des. 
2007, 13, 3368–3377. 
24. Zhu, N.; Shao, Y.; Xu, L.; Yu, L.; Sun, L. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK 
signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells. Mol. Biol. Rep. 
2009, 36, 2075–2085. 
25. Alpan, A.S.; Zencir, S.; Zupkó, I.; Coban, G.; Réthy, B.; Gunes, H.S.; Topcu, Z. Biological 
activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 
cells. J. Enzyme Inhib. Med. Chem. 2009, 24, 844–849. 
26. Ishar, M.P.; Singh, G.; Singh, S.; Sreenivasan, K.K. Design, synthesis, and evaluation of novel  
6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents. 
Bioorg. Med. Chem. Lett. 2006, 16, 1366–1370. 
27. Puskás, L.G.; Fehér, L.Z.; Vizler, C.; Ayaydin, F.; Rásó, E.; Molnár, E.; Magyary, I.; Kanizsai, I.; 
Gyuris, M.; Madácsi, R.; et al. Polyunsaturated fatty acids synergize with lipid droplet binding 
thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010, 9, 56. 
28. Fabian, G.; Farago, N.; Feher, L.Z.; Nagy, L.I.; Kulin, S.; Kitajka, K.; Bito, T.; Tubak, V.; 
Katona, R.L.; Tiszlavicz, L.; et al. High-density real-time PCR-based in vivo toxicogenomic 
screen to predict organ-specific toxicity. Int. J. Mol. Sci. 2011, 12, 6116–6134. 
29. Chellappan, S.P.; Giordano, A.; Fisher, P.B. Role of cyclin-dependent kinases and their inhibitors 
in cellular differentiation and development. Curr. Top. Microbiol. Immunol. 1998, 227, 57–103. 
30. Park, M.T.; Lee, S.J. Cell cycle and cancer. J. Biochem. Mol. Biol. 2003, 36, 60–65. 
Molecules 2014, 19 2076 
 
 
31. Pestell, R.G. New roles of cyclin D1. Am. J. Pathol. 2013, 183, 3–9. 
32. Pastan, I.; Gottesman, M.M.; Ueda, K.; Lovelace, E.; Rutherford, A.V.; Willingham, M.C.  
A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of 
P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA 1988, 85, 4486–4490. 
33. Molnár, J.; Szabó, D.; Mándi, Y.; Mucsi, I.; Fischer, J.; Varga, A.; Konig, S.; Motohashi, N. 
Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer 
Res. 1998, 18, 3033–3038. 
34. Réthy, B.; Zupkó, I.; Minorics, R.; Hohmann, J.; Ocsovszki, I.; Falkay, G. Investigation of 
cytotoxic activity on human cancer cell lines of arborinine and furanoacridones isolated from Ruta 
graveolens. Planta Med. 2007, 73, 41–48. 
35. Vermes, I.; Haanen, C.; Reutelingsperger, C. Flow cytometry of apoptotic cell death. J. Immunol. 
Methods 2000, 243, 167–190. 
36. Coban, G.; Zencir, S.; Zupkó, I.; Réthy, B.; Gunes, H.S.; Topcu, Z. Synthesis and biological 
activity evaluation of 1H-benzimidazoles via mammalian DNA topoisomerase I and cytostaticity 
assays. Eur. J. Med. Chem. 2008, 44, 2280–2285. 
37. Sarikaya, D.; Bilgen, C.; Kamataki, T.; Topcu, Z. Comparative cytochrome P450 -1A1, -2A6,  
-2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA 
level. Biopharm. Drug Dispos. 2006, 27, 353–359. 
38. Vass, L.; Kelemen, J.Z.; Fehér, L.Z.; Lorincz, Z.; Kulin, S.; Cseh, S.; Dormán, G.; Puskás, L.G. 
Toxicogenomics screening of small molecules using high-density, nanocapillary real-time PCR. 
Int. J. Mol. Med. 2009, 23, 65–74. 
39. Zupkó, I.; Réthy, B.; Hohmann, J.; Molnár, J.; Ocsovszki, I.; Falkay, G. Antitumor activity of 
alkaloids derived from Amaryllidaceae species. In Vivo 2009, 23, 41–48. 
40. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. 
Sample Availability: Not available. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
